Literature DB >> 27140398

Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis.

Jason J Winnick, Guillaume Kraft, Justin M Gregory, Dale S Edgerton, Phillip Williams, Ian A Hajizadeh, Maahum Z Kamal, Marta Smith, Ben Farmer, Melanie Scott, Doss Neal, E Patrick Donahue, Eric Allen, Alan D Cherrington.   

Abstract

Liver glycogen is important for the counterregulation of hypoglycemia and is reduced in individuals with type 1 diabetes (T1D). Here, we examined the effect of varying hepatic glycogen content on the counterregulatory response to low blood sugar in dogs. During the first 4 hours of each study, hepatic glycogen was increased by augmenting hepatic glucose uptake using hyperglycemia and a low-dose intraportal fructose infusion. After hepatic glycogen levels were increased, animals underwent a 2-hour control period with no fructose infusion followed by a 2-hour hyperinsulinemic/hypoglycemic clamp. Compared with control treatment, fructose infusion caused a large increase in liver glycogen that markedly elevated the response of epinephrine and glucagon to a given hypoglycemia and increased net hepatic glucose output (NHGO). Moreover, prior denervation of the liver abolished the improved counterregulatory responses that resulted from increased liver glycogen content. When hepatic glycogen content was lowered, glucagon and NHGO responses to insulin-induced hypoglycemia were reduced. We conclude that there is a liver-brain counterregulatory axis that is responsive to liver glycogen content. It remains to be determined whether the risk of iatrogenic hypoglycemia in T1D humans could be lessened by targeting metabolic pathway(s) associated with hepatic glycogen repletion.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27140398      PMCID: PMC4887181          DOI: 10.1172/JCI79895

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes.

Authors:  Preeti Kishore; Ilan Gabriely; Min-Hui Cui; Joseph Di Vito; Srikanth Gajavelli; Jong-Hee Hwang; Harry Shamoon
Journal:  Diabetes       Date:  2006-03       Impact factor: 9.461

2.  Effect of fast duration on disposition of an intraduodenal glucose load in the conscious dog.

Authors:  P Galassetti; K S Hamilton; F K Gibbons; D P Bracy; D B Lacy; A D Cherrington; D H Wasserman
Journal:  Am J Physiol       Date:  1999-03

3.  Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans.

Authors:  L Lecavalier; G Bolli; P Cryer; J Gerich
Journal:  Am J Physiol       Date:  1989-06

4.  Pancreas transplantation in diabetic humans normalizes hepatic glucose production during hypoglycemia.

Authors:  Z Barrou; E R Seaquist; R P Robertson
Journal:  Diabetes       Date:  1994-05       Impact factor: 9.461

5.  Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia.

Authors:  W P Borg; M J During; R S Sherwin; M A Borg; M L Brines; G I Shulman
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

6.  Hypothalamic AMP-activated protein kinase activation with AICAR amplifies counterregulatory responses to hypoglycemia in a rodent model of type 1 diabetes.

Authors:  X Fan; Y Ding; S Brown; L Zhou; M Shaw; M C Vella; H Cheng; E C McNay; R S Sherwin; R J McCrimmon
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-04-08       Impact factor: 3.619

7.  Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs.

Authors:  P S Hsieh; M C Moore; D W Neal; A D Cherrington
Journal:  Am J Physiol       Date:  1998-12

8.  Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release.

Authors:  W P Borg; R S Sherwin; M J During; M A Borg; G I Shulman
Journal:  Diabetes       Date:  1995-02       Impact factor: 9.461

9.  Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.

Authors:  J H Hwang; G Perseghin; D L Rothman; G W Cline; I Magnusson; K F Petersen; G I Shulman
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting.

Authors:  P J Boyle; S D Shah; P E Cryer
Journal:  Am J Physiol       Date:  1989-05
View more
  16 in total

1.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

2.  Salvianolate Reduces Glucose Metabolism Disorders in Dimethylnitrosamine-Induced Cirrhotic Rats.

Authors:  Li-Rui Tang; Yan-Yan Tao; Cheng-Hai Liu; Hai-Nan Wang
Journal:  Chin J Integr Med       Date:  2017-12-05       Impact factor: 1.978

Review 3.  The integrative biology of type 2 diabetes.

Authors:  Michael Roden; Gerald I Shulman
Journal:  Nature       Date:  2019-12-04       Impact factor: 49.962

4.  Effects of hepatic glycogen on food intake and glucose homeostasis are mediated by the vagus nerve in mice.

Authors:  Iliana López-Soldado; Rebeca Fuentes-Romero; Jordi Duran; Joan J Guinovart
Journal:  Diabetologia       Date:  2017-03-15       Impact factor: 10.122

5.  Morning Hyperinsulinemia Primes the Liver for Glucose Uptake and Glycogen Storage Later in the Day.

Authors:  Mary Courtney Moore; Marta S Smith; Ben Farmer; Katie C Coate; Guillaume Kraft; Masakazu Shiota; Phillip E Williams; Alan D Cherrington
Journal:  Diabetes       Date:  2018-04-17       Impact factor: 9.461

6.  Recurrent hypoglycemia inhibits the counterregulatory response by suppressing adrenal activity.

Authors:  Yunbing Ma; Qian Wang; Debria Joe; Manqi Wang; Matthew D Whim
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

7.  The kinetics of glucagon action on the liver during insulin-induced hypoglycemia.

Authors:  Christina Pedersen; Guillaume Kraft; Dale S Edgerton; Melanie Scott; Ben Farmer; Marta Smith; David C Laneve; Phillip E Williams; L Merkle Moore; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-03-24       Impact factor: 4.310

8.  Liver glycogen-induced enhancements in hypoglycemic counterregulation require neuroglucopenia.

Authors:  Shana O Warner; Abby M Wadian; Marta Smith; Ben Farmer; Yufei Dai; Nicole Sheanon; Dale S Edgerton; Jason J Winnick
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-03-29       Impact factor: 4.310

9.  Somatostatin Receptor Antagonism Reverses Glucagon Counterregulatory Failure in Recurrently Hypoglycemic Male Rats.

Authors:  Emily G Hoffman; Mahsa Jahangiriesmaili; Erin R Mandel; Caylee Greenberg; Julian Aiken; Ninoschka C D'Souza; Aoibhe Pasieka; Trevor Teich; Owen Chan; Richard Liggins; Michael C Riddell
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

10.  Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats.

Authors:  Christina Pedersen; Stephan D Bouman; Trine Porsgaard; Mette M Rosenkilde; Nikolaj K Roed
Journal:  Physiol Rep       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.